CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine

被引：0
|
作者：
Xinna Zhou
Guoliang Qiao
Xiaoli Wang
Qingkun Song
Michael A. Morse
Amy Hobeika
William R. Gwin
Jun Ren
H. Kim Lyerly
机构：
[1] Capital Medical University Cancer Center,Department of Medical Oncology, Beijing Key Laboratory for Therapeutic Cancer Vaccines
[2] Beijing Shijitan Hospital,Department of Medical Oncology
[3] Capital Medical University,Department of Medicine
[4] Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education),Department of Surgery
[5] Beijing Cancer Hospital and Institute,Department of Medicine
[6] Peking University School of Oncology,undefined
[7] Duke University Medical Center,undefined
[8] Duke University Medical Center,undefined
[9] University of Washington,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2018年 / 81卷
关键词：
CYP1A1; Single nucleotide polymorphism; Breast cancer; Liver metastasis; Docetaxel; Thiotepa; Capecitabine;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：365 / 372
页数：7
相关论文
共 50 条
  • [1] CYP1A1 genetic polymorphism is a promising predictor to improve chemotherapy effects in patients with metastatic breast cancer treated with docetaxel plus thiotepa vs. docetaxel plus capecitabine
    Zhou, Xinna
    Qiao, Guoliang
    Wang, Xiaoli
    Song, Qingkun
    Morse, Michael A.
    Hobeika, Amy
    Gwin, William R.
    Ren, Jun
    Lyerly, H. Kim
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2018, 81 (02) : 365 - 372
  • [2] Capecitabine plus docetaxel combination chemotherapy for metastatic breast cancer
    Saeki T.
    Takashima S.
    Breast Cancer, 2004, 11 (2) : 116 - 120
  • [3] A Multicenter Randomized Phase II Study of Docetaxel vs. Docetaxel Plus Cisplatin vs. Docetaxel Plus S-1 as Second-Line Chemotherapy in Metastatic Gastric Cancer Patients Who Had Progressed after Cisplatin Plus Either S-1 or Capecitabine
    Lee, Keun-Wook
    Kim, Bum Jun
    Kim, Mi-Jung
    Han, Hye Sook
    Kim, Jin Won
    Park, Young Lee
    Park, Sook Ryun
    CANCER RESEARCH AND TREATMENT, 2017, 49 (03): : 706 - 716
  • [4] A multicenter randomized phase II study of docetaxel vs. docetaxel plus cisplatin vs. docetaxel plus S-1 as second-line chemotherapy in metastatic gastric cancer patients who had progressed after cisplatin plus either S-1 or capecitabine
    Kim, B.
    Lee, K. W.
    Kim, M. J.
    Han, H. S.
    Park, Y. L.
    Park, S. R.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S432 - S432
  • [5] Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
    Dong, Ningning
    Yu, Jing
    Wang, Chaoying
    Zheng, Xiaohui
    Wang, Zheng
    Di, Lijun
    Song, Guohong
    Zhu, Budong
    Che, Li
    Jia, Jun
    Jiang, Hanfang
    Zhou, Xinna
    Wang, Xiaoli
    Ren, Jun
    JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2012, 138 (07) : 1197 - 1203
  • [6] Pharmacogenetic assessment of clinical outcome in patients with metastatic breast cancer treated with docetaxel plus capecitabine
    Ningning Dong
    Jing Yu
    Chaoying Wang
    Xiaohui Zheng
    Zheng Wang
    Lijun Di
    Guohong Song
    Budong Zhu
    Li Che
    Jun Jia
    Hanfang Jiang
    Xinna Zhou
    Xiaoli Wang
    Jun Ren
    Journal of Cancer Research and Clinical Oncology, 2012, 138 : 1197 - 1203
  • [7] Docetaxel plus capecitabine in the treatment of previous anthracycline-treated patients with metastatic breast cancer
    Bensalem, A.
    Bouzid, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] COST-EFFECTIVENESS EVALUATION OF THE USE OF CAPECITABINE plus DOCETAXEL VS GEMCITABINE plus DOCETAXEL IN PATIENTS WITH RECURRENT BREAST CANCER WHO PREVIOUSLY FAILED TO ANTHRACYCLINE CHEMOTHERAPY AND/OR WITH METASTATIC DISEASE
    Tenorio, C.
    Vargas, J.
    Martinez, J.
    VALUE IN HEALTH, 2009, 12 (07) : A271 - A271
  • [9] Impact of symptoms and toxicity on quality of life: Exploratory analysis of gemcitabine plus docetaxel vs capecitabine plus docetaxel in metastatic breast cancer.
    Fumoleau, P.
    Romieu, G.
    Chan, S.
    Huober, J.
    Tubiana-Hulin, M.
    Schneeweiss, A.
    Lluch, A.
    Bougnoux, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (18) : 48S - 48S
  • [10] Phase III Study of Gemcitabine Plus Docetaxel Compared With Capecitabine Plus Docetaxel for Anthracycline-Pretreated Patients With Metastatic Breast Cancer
    Chan, Stephen
    Romieu, Gilles
    Huober, Jens
    Delozier, Thierry
    Tubiana-Hulin, Michele
    Schneeweiss, Andreas
    Lluch, Ana
    Llombart, Antonio
    du Bois, Andreas
    Kreienberg, Rolf
    Mayordomo, Jose Ignacio
    Anton, Antonio
    Harrison, Mark
    Jones, Alison
    Carrasco, Eva
    Vaury, A. Thareau
    Frimodt-Moller, Bente
    Fumoleau, Pierre
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (11) : 1753 - 1760
12345